European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Hormone therapy for postmenopausal endometrial cancer survivors: a survey among Greek obstetricians-gynaecologists
D. Vavilis1, D. Tsolakidis1,*, D. G. Goulis1, P. Polichronou1, D. Kellartzis1, P. Tzevelekis1, B. C. Tarlatzis1
1 First Department of Obstetrics and Gynaecology, “Papageorgiou” General Hospital, Aristotle University of Thessaloniki (Greece)
Eur. J. Gynaecol. Oncol. 2011, 32(1), 81–83;
Published: 10 February 2011
Purpose of investigation: In this study we evaluated the prescription attitude of Greek obstetricians-gynaecologists towards hormone replacement therapy (HRT) for endometrial cancer survivors. Methods: An anonymous questionnaire was sent to 900 members of the Hellenic Society of Obstetrics and Gynaecology, presenting a hypothetical case of an endometrial cancer survivor with indications for HRT, followed by a series of relevant questions. Results: Three hundred and three valid responses were received and analysed according to age, gender and practice setting. HRT would be prescribed by 30.4% of gynaecologists; as far as type of regimen is concerned, 67.4% would prescribe tibolone, 22.8% estrogen-only and 9.8% estrogen plus progestagen. In contrast, 69.6% would not prescribe HRT due to the fear of endometrial cancer recurrence (88.2%), development of breast cancer (2.8%) or both (4.7%); among them, 28.4% would prescribe central nervous system (CNS) medications, selective estrogen receptor modulators (SERMs), phyto-oestrogens or biphosphonates, as alternates. Conclusions: One out of three Greek gynaecologists would prescribe HRT to endometrial cancer survivors. Alternative therapies, mainly CNS medications, would be suggested by the opposers.
Endometrial cancer survivors
Hormone replacement therapy
Estrogen replacement therapy